Head-to-head comparison
| Property | Hexarelin | Ipamorelin |
|---|---|---|
| Category | Muscle & Growth | Muscle & Growth |
| Legal Status | Research Only | Reclassification Pending |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~55-70 minutes | ~2 hours |
| Mol. Weight | 887.04 Da | 711.85 Da |
| Side Effects | Increased cortisol (dose-dependent), Increased prolactin, Water retention | Headache, Flushing, Injection site pain |
Key differences
- GH release potency: Hexarelin is one of the most potent GH-releasing peptides, producing larger acute GH spikes than ipamorelin at comparable doses.
- Selectivity: Ipamorelin is highly selective for GH release with minimal effects on cortisol, prolactin, and ACTH; hexarelin increases cortisol and prolactin at higher doses.
- Desensitization: Hexarelin is known to cause receptor desensitization with chronic use, reducing efficacy over time; ipamorelin shows less desensitization in reported protocols.
- Appetite effects: Hexarelin can increase appetite (ghrelin pathway); ipamorelin has minimal appetite stimulation due to its receptor selectivity.
- Cardiac effects: Hexarelin has published research on cardioprotective effects via a non-GHS-R pathway (CD36 receptor); ipamorelin does not have this secondary activity.
- Clinical data: Both have limited human clinical data; hexarelin has some published human studies including cardiac research. Ipamorelin has Phase II data.
- Typical dosing: Hexarelin is commonly dosed at 100–200 mcg 2–3 times daily; ipamorelin at 200–300 mcg 2–3 times daily.
The verdict
The choice between hexarelin and ipamorelin is a potency-versus-selectivity tradeoff. Hexarelin produces stronger GH pulses and has unique cardioprotective research, but causes cortisol and prolactin elevation and is prone to desensitization. Ipamorelin is the cleaner option with minimal off-target hormonal effects and sustained efficacy, making it the more commonly recommended GH peptide in most protocols. Hexarelin may be preferred for short-term protocols where maximum GH stimulation is prioritized.
Frequently asked questions
Hexarelin produces larger acute GH spikes and is considered one of the most potent GH-releasing peptides. However, this potency comes with cortisol and prolactin elevation that ipamorelin avoids. Ipamorelin provides a strong but cleaner GH response.
Yes, hexarelin is known to cause ghrelin receptor desensitization with chronic use, meaning its GH-releasing effect diminishes over time. This is a significant disadvantage compared to ipamorelin, which shows less desensitization in reported protocols. Hexarelin is often cycled to manage this issue.
Yes, hexarelin increases cortisol and prolactin, particularly at higher doses. Ipamorelin is specifically prized for its selectivity — it stimulates GH release without significantly affecting cortisol, prolactin, or ACTH levels.
Hexarelin has published research suggesting cardioprotective effects through the CD36 receptor, a pathway separate from its GH-releasing activity. This is unique among GH secretagogues. However, clinical applications for cardiac protection have not been established.
Both act on the ghrelin receptor pathway, so combining them would produce additive but potentially redundant GH stimulation. A more common strategy is pairing one ghrelin-pathway peptide (like ipamorelin) with a GHRH analog (like CJC-1295) for synergistic release through two different pathways.